Globin-chain specificity of oxidation-induced changes in red blood cell membrane properties.
We have previously shown that excess unpaired alpha- and beta-globin chains in severe alpha- and beta-thalassemia interacting with the membrane skeleton induce different changes in membrane properties of red blood cells (RBCs) in these two phenotypes. We suggest that these differences in membrane material behavior may reflect the specificity of the membrane damage induced by alpha- and beta-globin chains. To further explore this hypothesis, we sought in vitro models that induce similar membrane alterations in normal RBCs. We found that treatment of normal RBCs with phenylhydrazine produced rigid and mechanically unstable membranes in conjunction with selective association of oxidized alpha-globin chains with the membrane skeleton, features characteristic of RBCs in severe beta-thalassemia. Methylhydrazine, in contrast, induced selective association of oxidized beta-globin chains with the membrane skeleton and produced rigid but hyperstable membranes, features that mimicked those of RBCs in severe alpha-thalassemia. These findings suggest that consequences of oxidation induced by globin chains are quite specific in that those agents that cause alpha-globin chain accumulation at the membrane produce rigid but mechanically unstable membranes, whereas membrane accumulation of beta-globin chains results in rigid but mechanically stable membranes. These in vitro experiments lend further support to the hypothesis that membrane-associated alpha- and beta-chains induce oxidative damage to highly specific different skeletal components and that the specificity of this skeletal damage accounts for the differences in material membrane properties of these oxidatively attacked RBCs and perhaps of alpha- and beta-thalassemic RBCs as well.
Schrier
S L
SL
Division of Hematology, Stanford University School of Medicine, CA 94305-5112.
Mohandas
N
N
D004907:Erythrocyte Deformability; D004910:Erythrocyte Membrane / Q000737:chemistry / Q000378:metabolism*; D005914:Globins / Q000032:analysis / Q000378:metabolism*; D006801:Humans; D008773:Methylphenazonium Methosulfate / Q000494:pharmacology; D009002:Monomethylhydrazine / Q000494:pharmacology; D010084:Oxidation-Reduction; D010659:Phenylhydrazines / Q000494:pharmacology; D013789:Thalassemia / Q000097:blood*
D010659:Phenylhydrazines; C030299:phenylhydrazine; D008773:Methylphenazonium Methosulfate; D005914:Globins; D009002:Monomethylhydrazine